MX370670B - Combinaciones que comprenden brexipiprazol o una sal del mismo y un segundo farmaco para el uso en el tratamiento de un trastorno del sistema nervioso central. - Google Patents
Combinaciones que comprenden brexipiprazol o una sal del mismo y un segundo farmaco para el uso en el tratamiento de un trastorno del sistema nervioso central.Info
- Publication number
- MX370670B MX370670B MX2013010796A MX2013010796A MX370670B MX 370670 B MX370670 B MX 370670B MX 2013010796 A MX2013010796 A MX 2013010796A MX 2013010796 A MX2013010796 A MX 2013010796A MX 370670 B MX370670 B MX 370670B
- Authority
- MX
- Mexico
- Prior art keywords
- drug
- salt
- reuptake inhibitor
- antidepressant
- brexpiprazole
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
Abstract
La presente invención proporciona un medicamento que tiene un mayor espectro de tratamiento, causando menores efectos colaterales y que es superior en tolerabilidad y seguridad, en comparación con agentes antipsicóticos típicos y agentes antipsicóticos atípicos conocidos. La presente invención se refiere a un medicamento que contiene (I) un compuesto que es 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoxi]-1H-quinolin-2- ona o una de sus sales y (II) al menos un fármaco seleccionado del grupo que consiste en un estabilizador del estado de ánimo, un inhibidor de la reabsorción de serotonina, un inhibidor de la reabsorción de norepinefrina, un inhibidor de la reabsorción de serotonina y norepinefrina, un antidepresivo noradrenérgico y serotonérgico específico, un fármaco antiansiedad, un antidepresivo tricíclico, un antidepresivo tetracíclico, un fármaco antipsicótico y un fármaco anti-ADHD, en combinación.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161471911P | 2011-04-05 | 2011-04-05 | |
US201161580540P | 2011-12-27 | 2011-12-27 | |
PCT/JP2012/059825 WO2012137971A1 (en) | 2011-04-05 | 2012-04-04 | Combinations comprising brexpiprazole or a salt thereof and a second drug for use in the treatment of a cns disorder |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013010796A MX2013010796A (es) | 2013-12-06 |
MX370670B true MX370670B (es) | 2019-12-19 |
Family
ID=46045045
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013010796A MX370670B (es) | 2011-04-05 | 2012-04-04 | Combinaciones que comprenden brexipiprazol o una sal del mismo y un segundo farmaco para el uso en el tratamiento de un trastorno del sistema nervioso central. |
MX2019015237A MX2019015237A (es) | 2011-04-05 | 2013-09-20 | Combinaciones que comprenden brexpiprazol o una sal del mismo y un segundo farmaco para el uso en el tratamiento de un trastorno del sistema nervioso central. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019015237A MX2019015237A (es) | 2011-04-05 | 2013-09-20 | Combinaciones que comprenden brexpiprazol o una sal del mismo y un segundo farmaco para el uso en el tratamiento de un trastorno del sistema nervioso central. |
Country Status (31)
Country | Link |
---|---|
US (5) | US20140120185A1 (es) |
EP (4) | EP2694043B1 (es) |
JP (2) | JP5992924B2 (es) |
KR (1) | KR101890450B1 (es) |
CN (2) | CN108042808B (es) |
AR (1) | AR085840A1 (es) |
AU (1) | AU2012240864B2 (es) |
BR (1) | BR112013025420B1 (es) |
CA (1) | CA2832157C (es) |
CO (1) | CO6801769A2 (es) |
CY (1) | CY1120567T1 (es) |
DK (1) | DK2694043T3 (es) |
EA (1) | EA035837B1 (es) |
ES (1) | ES2654851T3 (es) |
HK (1) | HK1246159A1 (es) |
HR (1) | HRP20180098T1 (es) |
HU (1) | HUE035542T2 (es) |
IL (1) | IL228669B (es) |
JO (2) | JOP20120083B1 (es) |
LT (1) | LT2694043T (es) |
MX (2) | MX370670B (es) |
MY (1) | MY166936A (es) |
NZ (1) | NZ615591A (es) |
PL (1) | PL2694043T3 (es) |
PT (1) | PT2694043T (es) |
RS (1) | RS56802B1 (es) |
SG (2) | SG10201602326RA (es) |
SI (1) | SI2694043T1 (es) |
TW (1) | TWI636784B (es) |
WO (1) | WO2012137971A1 (es) |
ZA (1) | ZA201306981B (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3753B1 (ar) * | 2011-10-14 | 2021-01-31 | Otsuka Pharma Co Ltd | قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه |
TWI632921B (zh) * | 2011-10-19 | 2018-08-21 | 大塚製藥股份有限公司 | 口服溶液 |
TW201332572A (zh) * | 2011-12-28 | 2013-08-16 | Otsuka Pharma Co Ltd | 具有經取代的β-環糊精之藥物製劑 |
JOP20200109A1 (ar) | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
JOP20210047A1 (ar) * | 2012-10-25 | 2017-06-16 | Otsuka Pharma Co Ltd | عامل وقائي و/أو علاجي للأعراض السلوكية والنفسية المصحوبة بمرض تنكسي عصبي أو الأعراض الإندفاعية المصحوبة بمرض ذهني، يحتوي على بريكسبيرازول أو ملحه |
SG11201608766TA (en) | 2014-04-22 | 2016-11-29 | Otsuka Pharma Co Ltd | Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders |
WO2015188092A1 (en) * | 2014-06-06 | 2015-12-10 | Rhodes Pharmaceuticals, L.P. | Methods for treating attention deficit hyperactivity disorder with methylphenidate |
CA2936748C (en) | 2014-10-31 | 2017-08-08 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
AU2017240259A1 (en) | 2016-04-01 | 2018-10-18 | Upmc | Regulatory device and associated method |
US11123300B2 (en) | 2016-08-16 | 2021-09-21 | Hexal Ag | Immediate release tablet of a benzothiophene compound |
EP3500249A1 (en) | 2016-08-16 | 2019-06-26 | Hexal Aktiengesellschaft | Pharmaceutical compositions of a benzothiophene compound |
DK3532064T3 (da) * | 2016-10-28 | 2020-08-24 | H Lundbeck As | Kombinationsbehandlinger omfattende imidazopyrazinoner til behandlingen af psykiatriske og/eller kognitive lidelser |
GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
EP3501506B1 (en) * | 2017-12-19 | 2019-10-09 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Pharmaceutical tablet composition comprising brexpiprazole |
JP6831354B2 (ja) * | 2018-08-16 | 2021-02-17 | 株式会社Dnpファインケミカル | 接着性組成物からなる錠剤、その製造方法、及び該錠剤を用いた部材又は部品の製造方法 |
JP2019183095A (ja) * | 2018-08-16 | 2019-10-24 | 株式会社Dnpファインケミカル | 接着性粉体、接着性錠剤の製造方法、接着性錠剤、並びに該接着性粉体及び錠剤を用いた部材又は部品の製造方法 |
BR112021007745A2 (pt) * | 2018-10-24 | 2021-07-27 | Effector Therapeutics, Inc. | formas cristalinas de inibidores de mnk |
US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
TW202103699A (zh) | 2019-04-17 | 2021-02-01 | 英商康派斯百事威公司 | 賽洛西賓(psilocybin)於憂鬱及其他各種失調症之治療 |
JPWO2021029020A1 (es) * | 2019-08-13 | 2021-02-18 | ||
US11229644B1 (en) * | 2020-12-31 | 2022-01-25 | Lake O'hara Llc | Methods of treating psychiatric disorders in obese patients with brexpiprazole |
CN113322299A (zh) * | 2021-05-28 | 2021-08-31 | 南昌大学 | 一种抑郁症和药物成瘾疾病的药物靶点识别方法 |
US20240009181A1 (en) * | 2022-07-08 | 2024-01-11 | Jason Eric Schiffman | Method for the treatment and prophylaxis of substance-related and/or addictive disorders including substance/medication-induced depressive disorders, bipolar and related disorders, and anxiety disorders and compositions useful for the same |
US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5178878A (en) | 1989-10-02 | 1993-01-12 | Cima Labs, Inc. | Effervescent dosage form with microparticles |
IL121076A (en) * | 1996-06-19 | 2000-10-31 | Akzo Nobel Nv | Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors |
IL123716A (en) * | 1997-03-27 | 2001-03-19 | Akzo Nobel Nv | Therapeutic combinations of mirtazapine and an antipsychotic agent |
US6024981A (en) | 1997-04-16 | 2000-02-15 | Cima Labs Inc. | Rapidly dissolving robust dosage form |
US20040176466A1 (en) * | 2001-08-08 | 2004-09-09 | Allen Albert John | Combination therapy for the treatment of neurological disorders |
MXPA05006857A (es) * | 2002-12-27 | 2005-08-18 | Otsuka Pharma Co Ltd | Derivados de carbostirilo e inhibidores de la recaptacion de serotonina para el tratamiento de desordenes en el humor. |
CA2601716C (en) * | 2004-06-25 | 2011-05-31 | Board Of Regents, The University Of Texas System | Methods and compositions for the treatment of attention deficit hyperactivity disorder and hyperphenylalanemia |
JP4315393B2 (ja) * | 2005-04-14 | 2009-08-19 | 大塚製薬株式会社 | 複素環化合物 |
TWI320783B (en) | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
JP4540700B2 (ja) * | 2006-10-13 | 2010-09-08 | 大塚製薬株式会社 | 医薬 |
DE602007010818D1 (de) * | 2006-10-27 | 2011-01-05 | Janssen Pharmaceutica Nv | Verfahren zur behandlung disruptiver verhaltensstörungen |
JP2008189616A (ja) * | 2007-02-07 | 2008-08-21 | Mitsubishi Tanabe Pharma Corp | 注意欠陥多動性障害の治療薬 |
JP2011136906A (ja) * | 2008-04-18 | 2011-07-14 | Otsuka Pharmaceut Co Ltd | 複素環化合物 |
-
2012
- 2012-04-03 JO JOP/2012/0083A patent/JOP20120083B1/ar active
- 2012-04-03 TW TW101111875A patent/TWI636784B/zh active
- 2012-04-03 AR ARP120101135A patent/AR085840A1/es unknown
- 2012-04-04 EP EP12719460.3A patent/EP2694043B1/en not_active Revoked
- 2012-04-04 RS RS20180064A patent/RS56802B1/sr unknown
- 2012-04-04 EA EA201391450A patent/EA035837B1/ru not_active IP Right Cessation
- 2012-04-04 EP EP22155365.4A patent/EP4023223A1/en active Pending
- 2012-04-04 MY MYPI2013701740A patent/MY166936A/en unknown
- 2012-04-04 WO PCT/JP2012/059825 patent/WO2012137971A1/en active Application Filing
- 2012-04-04 EP EP17198877.7A patent/EP3299018A1/en not_active Withdrawn
- 2012-04-04 SG SG10201602326RA patent/SG10201602326RA/en unknown
- 2012-04-04 BR BR112013025420-3A patent/BR112013025420B1/pt active IP Right Grant
- 2012-04-04 US US14/009,436 patent/US20140120185A1/en not_active Abandoned
- 2012-04-04 LT LTEP12719460.3T patent/LT2694043T/lt unknown
- 2012-04-04 EP EP19205895.6A patent/EP3626243A1/en not_active Withdrawn
- 2012-04-04 AU AU2012240864A patent/AU2012240864B2/en active Active
- 2012-04-04 CN CN201810096214.1A patent/CN108042808B/zh active Active
- 2012-04-04 DK DK12719460.3T patent/DK2694043T3/en active
- 2012-04-04 JP JP2013546481A patent/JP5992924B2/ja active Active
- 2012-04-04 PL PL12719460T patent/PL2694043T3/pl unknown
- 2012-04-04 SG SG2013069273A patent/SG193468A1/en unknown
- 2012-04-04 KR KR1020137029250A patent/KR101890450B1/ko active IP Right Grant
- 2012-04-04 CA CA2832157A patent/CA2832157C/en active Active
- 2012-04-04 MX MX2013010796A patent/MX370670B/es active IP Right Grant
- 2012-04-04 ES ES12719460.3T patent/ES2654851T3/es active Active
- 2012-04-04 SI SI201231192T patent/SI2694043T1/en unknown
- 2012-04-04 HU HUE12719460A patent/HUE035542T2/hu unknown
- 2012-04-04 PT PT127194603T patent/PT2694043T/pt unknown
- 2012-04-04 NZ NZ615591A patent/NZ615591A/en unknown
- 2012-04-04 CN CN201280017329.8A patent/CN103547260B/zh active Active
-
2013
- 2013-09-17 ZA ZA2013/06981A patent/ZA201306981B/en unknown
- 2013-09-20 MX MX2019015237A patent/MX2019015237A/es unknown
- 2013-10-01 IL IL228669A patent/IL228669B/en active IP Right Grant
- 2013-11-05 CO CO13261085A patent/CO6801769A2/es not_active Application Discontinuation
-
2014
- 2014-05-09 HK HK18105601.0A patent/HK1246159A1/zh unknown
-
2016
- 2016-08-18 JP JP2016160872A patent/JP2017031155A/ja active Pending
- 2016-12-21 US US15/386,289 patent/US20170100395A1/en not_active Abandoned
-
2017
- 2017-10-19 US US15/788,102 patent/US20180042923A1/en not_active Abandoned
-
2018
- 2018-01-17 CY CY20181100057T patent/CY1120567T1/el unknown
- 2018-01-18 HR HRP20180098TT patent/HRP20180098T1/hr unknown
- 2018-07-20 US US16/041,246 patent/US20180325894A1/en not_active Abandoned
-
2021
- 2021-02-25 JO JOP/2021/0035A patent/JOP20210035A1/ar unknown
- 2021-03-10 US US17/197,725 patent/US20220000861A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20210035A1 (ar) | توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns | |
EA201171493A1 (ru) | МОТИВЫ ХИМИЧЕСКИХ МОДИФИКАЦИЙ ДЛЯ ИНГИБИТОРОВ И МИМЕТИКОВ мкРНК | |
CO6501189A2 (es) | Derivados de oxazina y su uso en el tratamiento de los trastornos neurológicos | |
EA201490272A1 (ru) | Новые 4-пиперидинильные соединения для применения в качестве ингибиторов танкиразы | |
MA31358B1 (fr) | Méthodes de traitement du cancer à l'aide d'inhibiteurs de pi3k alpha à base de pyridopyrimidinone | |
MX371279B (es) | Agente profiláctico y/o terapéutico para síntomas conductuales y psicológicos asociados con la enfermedad neurodegenerativa o síntomas impulsivos asociados con enfermedad mental que contiene brexpiprazol o sales del mismo. | |
DOP2009000232A (es) | Metanoisoindoles y dionas de éstos como agentes anti-psicóticos. | |
MA32784B1 (fr) | Composes aryles substitues par heterocycle comme inhibiteurs de hif | |
IN2014DN09804A (es) | ||
EA201591195A1 (ru) | Новые хинолоновые производные | |
JO3148B1 (ar) | مركب مثبط لإشارات مسار notch | |
MX337440B (es) | Antagonistas de trpv4. | |
EA201200247A1 (ru) | Новые азагетероциклические соединения | |
MX2014000964A (es) | Derivados aza heterociclicos sustituidos. | |
EP2416795A4 (en) | COGNITIVE DECLINE INHIBITORS | |
UA104880C2 (uk) | Заміщені тетрагідропіранспіропіролідинон і тетрагідропіранспіропіперидинон, спосіб їх одержання й застосування в лікувальних цілях | |
NI201000176A (es) | 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas. | |
EA200970849A1 (ru) | Трициклические производные изохинолина для лечения ожирения | |
EA201170997A1 (ru) | Производные индола в качестве противораковых агентов | |
EA201270556A1 (ru) | Конденсированные тиазоло и оксазолопиримидиноны | |
MX2012007253A (es) | Derivados triciclicos y sus usos y composiciones farmaceuticas. | |
MX2011012596A (es) | Metodos para incrementar os efectos de un inhibidor selectivo de la recaptacion de serotonina en los mamiferos. | |
MX2010004314A (es) | Compuestos para inhibir la actividad de quinesina de la proteina quinesina del huso. | |
MX2010004315A (es) | Compuestos para inhibir la actividad de quinesina ksp. | |
MX2010004313A (es) | Compuestos para inhibir la actividad de quinesina de la proteina de quinesina del huso. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |